CTTC’s Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment Read more »

VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare® Pain Therapy Treatment Read more »

Walter Reed Army Medical Center to treat pain patients with CTT’s Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S Read more »

Enrollment complete in Paradigm Spine’s comparative study of coflex interlaminar technology

Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced today that it has completed patient enrollment in an Investigational Device Exemption pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis. Read more »

Paradigm Spine Completes Enrollment in Pivotal Clinical Study of coflex® Interlaminar Technology (Business Wire via Yahoo! Finance)

NEW YORK----Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced today that it has completed patient enrollment in an Investigational Device Exemption pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis. Read more »

Alphatec Spine Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Scient’x Groupe S.A.S. (GlobeNewswire via Yahoo! Finance)

CARLSBAD, Calif. -- Alphatec Holdings, Inc. , the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that the Hart-Scott-Rodino review period for Alphatec Spine's proposed acquisition of Scient'x ... Read more »